Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jan 14, 2011


Caris Life Sciences announced this week that Amy Jensen Cunniffe has joined the company in the newly created position of senior vice president for government affairs. In this role, Cunniffe will be tasked with establishing Caris's Washington DC office where she will lead its public policy and government relations efforts, the company said.

Previously, Cunniffe was leader of GE Healthcare's government relations team. Prior to that she was a director at lobbying firm Quinn Gillespie and Associates and a special assistant to the president for legislative affairs during the term of President George W. Bush.

Nonlinear Dynamics announced this week it has added Leonhard Pollack and Mark Pittman to its international sales team. Pollack, who is based in Germany, will be covering the German, Austrian, and Finnish markets; while Pittman, based on the West Coast of the US, will be working with the company's US sales team.

Pollack was previously a senior mass spec sales specialist at Waters. Pittman joins the company from informatics firm Proteome Software.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.